Summary:
- Novo Nordisk, a leading pharmaceutical company, has signed a $2.1 billion deal to develop new obesity medication.
- The deal involves collaborating with another company, Dicerna Pharmaceuticals, to create innovative obesity treatments using advanced technology.
- These new obesity pills could help people struggling with weight issues, providing a potential solution to a growing health concern.